Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 22, Issue 9, 2000, Pages 695-705

  Isaza, C A ^a   Henao, J ^a   Lopez A M ^a   Cacabelos, R ^a  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

Author keywords

CYP2D6 gene; Cytochrome P450; Drug metabolism; Genetic polymorphism; Pharmacogenetics

Indexed keywords

AMITRIPTYLINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; CODEINE; CYTOCHROME P450 2D6; DESIPRAMINE; DIHYDROCODEINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; METHADONE; MIANSERIN; MINAPRINE; MORPHINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; PETHIDINE; PROMETHAZINE; REBOXETINE; RISPERIDONE; THIORIDAZINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BIOTRANSFORMATION; COLOMBIA; DRUG METABOLISM; ENZYME INACTIVATION; ENZYME SUBSTRATE; FEMALE; GENE FREQUENCY; GENE ISOLATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PHARMACOGENETICS; POPULATION RESEARCH;

ADOLESCENT; ADULT; ALLELES; COLOMBIA; CYTOCHROME P-450 CYP2D6; DNA; DNA PRIMERS; ELECTROPHORESIS, AGAR GEL; FEMALE; GENE DELETION; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHENOTYPE;

EID: 0034469337     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2000.22.9.802286     Document Type: Article

References (65)

1. Pharmacokinetics
2. Update: Clinically significant cytochrome P450 drug interactions
3. Pharmacogenomics: Translating functional genomics into rational therapeutics
4. Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs
5. Human debrisoquine 4-hydroxylase (P450 II D I): cDNA and deduced amino acid sequence and assignment of the CYP locus to chromosome 22
6. Molecular mechanisms of genetic polymorphisms of drug metabolism
7. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
8. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra rapid metabolism of debrisoquine
9. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
10. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population
11. Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies
12. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
13. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
14. Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype
15. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes
16. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
17. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
18. Frequent distribution of ultrarapid metabolizers of debrisoquine in a Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
19. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2EI in the South-Amerindian population of Chile
20. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: Role of selection versus drift in world populations
21. Dextromethorphan O-demethylation polymorphism in the Uruguayan population
22. Principles of drug therapy
23. Genetic variation as a guide to drug development
24. Influence of pharmacogenetics on drug disposition and response
25. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication
26. Aislamiento y secuenciación del gen CYP2D6 metabolizador de fármacos
27. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene
28. Nomenclature for human CYP2D6 alleles
29. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
30. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction
31. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
32. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
33. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
34. 226 in exon I of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15
35. PCR-based genotyping for duplicated and deleted CYP2D6 genes
36. Why hypertensive patients vary in their response to oral debrisoquine
37. A probably genetic defect of the metabolism of sparteine
38. Debrisoquine-type polymorphism of drug oxidation; purification front human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation
39. The genetic control of drug oxidation in the liver
40. The P450 superfamily, update on new sequences, gene mapping and recommended nomenclature
41. A nomenclature system for metabolic gene polymorphism
42. 1934 base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site
43. Multiple mutations of the human cytochrome P450 II D6 gene (CYP2D6) in poor metabolizers of debrisoquine
44. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
45. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population
46. An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes, a study in the Ngawbé guaymi Amerindians of Panama
47. Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama
48. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population
49. Cytochrome P450 CYP2D6
50. Pronounced differences betwen native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
51. Correlation between cytochrome P450 CYP2D6 (CYP2D6) genotype and phenotype
52. Citalopram: An interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype
53. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
54. Venlafaxine serum levels and CYP2D6 genotype
55. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes
56. CYP2D6 inhibition in patients treated with sertraline
57. Cytochrome P450 CYP2D6 genotype and steady slate plasma levels of riesperidone and 9-hydroxyrisperidone
58. CYP2D6 Hhal genotype and the neuroleptic malignant syndrome
59. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
60. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease
61. Alternative splicing patterns of CYP2D genes in human brain and degenerative disorders
62. Cytochrome P450 2D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians
63. Xenobiotic-metabolizing enzymes and cancer risk: Correspondence between genotype and phenotype